Authors

• Marion Dahlke
• Amy K. Mottl (ORCID: https://orcid.org/0000-0002-4258-1726)
• Sung-Gyun Kim
• Soo Kun Lim (ORCID: https://orcid.org/0000-0001-7589-5150)
• Amit Lodha
• Jessica Ryan (ORCID: https://orcid.org/0000-0003-2007-6021)
• Gianna Mastroianni Kirsztajn (ORCID: https://orcid.org/0000-0003-1317-4109)
• Mei Sian Fu
• Yasmin Brahmbhatt (ORCID: https://orcid.org/0000-0001-8718-9368)
• Greggory Housler (ORCID: https://orcid.org/0000-0002-1151-7166)
• Jose Barros Neto
• Rong Jiao
• Sradha S. Kotwal
• Jonathan Barratt
• on behalf of the Atrasentan and Sodium Glucose Co-transporter-2 Inhibitor Efficacy and Safety Trial (Assist) Investigator Group
• Irene L. Noronha
• Hiddo J.L. Heerspink
• Jose Luis Górriz

Institutions

• University of North Carolina at Chapel Hill (US)
• Novartis (Switzerland) (CH)
• University Medical Center Groningen (NL)
• University of Leicester (GB)
• Universitat de València (ES)
• University of Groningen (NL)
• Universidade de São Paulo (BR)
• Leicester General Hospital (GB)
• Sultanah Aminah Hospital (MY)
• UNSW Sydney (AU)
• University of Malaya (MY)
• Prince of Wales Hospital (AU)
• The George Institute for Global Health (AU)
• Novartis (United States) (US)
• Monash Health (AU)
• Brazilian Society of Speech (BR)
• INCLIVA Health Research Institute (ES)
• Hallym University Sacred Heart Hospital (KR)
• Universidade Federal de São Paulo (BR)

Publication Details

Journal

Journal of the American Society of Nephrology

Published

2026-03-29

DOI

https://doi.org/10.1681/asn.0000001076

Primary Topic

Renal Diseases and Glomerulopathies

Type

article

Field-Weighted Citation Impact

0.00